[Rapporto di ricerca] Si prevede che il mercato dei prodotti biofarmaceutici crescerà da 3.29.966,22 milioni di dollari nel 2022 a 7.00.873,94 milioni di dollari entro il 2028; si prevede che crescerà a un CAGR del 13,4% dal 2022 al 2028.
Le crescenti applicazioni nella terapia del cancro e il potenziale per il trattamento di malattie rare sono alcuni dei fattori che guidano la crescita del mercato biofarmaceutico.
< p>Secondo il rapporto del National Cancer Institute, il cancro è tra le principali cause di morte a livello globale. Ad esempio, nel 2018, si sono verificati 18,1 milioni di nuovi casi di cancro e 9,5 milioni di decessi correlati al cancro in tutto il mondo. Entro il 2040, si prevede che i nuovi casi di cancro saliranno a 29,5 milioni, con i decessi correlati al cancro a 16,4 milioni. Il rapporto del Dipartimento della Salute e dei Servizi Umani degli Stati Uniti afferma che il tasso di nuovi casi di cancro ai polmoni e ai bronchi è di 52,0 ogni 100.000 uomini e donne all'anno. Il numero stimato di nuovi casi di cancro ai polmoni e ai bronchi è stato di 236.740 nel 2022, ovvero il 12,3% di tutti i nuovi casi di cancro. I prodotti biofarmaceutici offrono nuove opportunità per ottenere il controllo su un’incidenza così elevata di cancro. Basandosi sulla comprensione dei meccanismi biologici sottostanti e del ruolo del sistema immunitario dei pazienti nella lotta contro il cancro, i ricercatori biofarmaceutici stanno producendo nuovi farmaci responsabili del trattamento di diversi tipi di cancro. Questi vanno dalla terapia con cellule CAR-T agli inibitori del checkpoint immunitario e ai farmaci personalizzati, mirati ai difetti genetici che si traducono in una specifica condizione tumorale. Un rapporto della Pharmaceutical Research and Manufacturers of America (PhRMA) rivela che sei terapie CAR-T sono state approvate dalla Food and Drug Administration (FDA) statunitense per il trattamento di un’ampia gamma di tipi di cancro, compresi i casi di cancro pediatrico. Inoltre, il rapporto PhRMA rivela che altri approcci terapeutici, come l’mRNA con il potenziale di trasformare un’ampia gamma di tumori, hanno ottenuto approvazioni. Ad esempio, nel febbraio 2023, mRNA-4157/V940, un vaccino sperimentale contro il cancro a mRNA personalizzato di Moderna, Inc. e Merck, è stato riconosciuto come terapia rivoluzionaria, in combinazione con KEYTRUDA, dalla USFDA. Inoltre, più di 1.300 farmaci e vaccini per il trattamento di vari tipi di cancro sono attualmente in fase di sperimentazione clinica o sono in attesa di approvazione da parte della FDA. Questi comprendono immunoterapie (anticorpi monoclonali e CAR-T), editing genetico per il cancro bersaglio, terapie virali oncolitiche e coniugati di anticorpi e farmaci (ADC) che prendono di mira cellule tumorali specifiche senza danneggiare le cellule normali.< em>Fonte: PhRMA's Medicines in Development for Cancer, dicembre 2020
Pertanto, la crescente incidenza dei tumori a livello globale si traduce nella domanda di strumenti diagnostici sicuri, efficaci ed efficienti sistemi, come i prodotti biofarmaceutici.
Approfondimenti strategici
Approfondimento sui segmenti applicativi
In base all'applicazione, il mercato dei prodotti biofarmaceutici è segmentato in oncologia, antinfiammatori e sistemi biofarmaceutici. malattie infettive, disturbi autoimmuni, disturbi metabolici, disturbi ormonali e amp; fallimento della crescita, malattie cardiovascolari, malattie neurologiche e altri. Il segmento oncologico deteneva la quota maggiore del mercato nel 2022. Tuttavia, si prevede che il segmento delle malattie infiammatorie e infettive registrerà il CAGR più elevato durante il periodo di previsione. Secondo il rapporto del National Institute of Health (NIH), il cancro è una malattia genetica invasiva complessa che causa una mortalità significativa a livello globale. Ad esempio, i biofarmaci a base di proteine hanno allungato significativamente la vita di milioni di malati di cancro. Inoltre, diverse importanti aziende hanno avviato una collaborazione di ricerca per lo sviluppo di una nuova tecnologia terapeutica basata su proteine mirate per il trattamento del cancro. Ad esempio, nell'aprile 2022, Ubix Therapeutics ha annunciato una collaborazione con SK Biopharmaceuticals per sviluppare nuovi composti e farmaci attraverso la tecnologia Degraducer di Ubix per il trattamento del cancro. Tali fattori sopra menzionati sono responsabili della crescita del segmento, contribuendo così alla crescita del mercato dei prodotti biofarmaceutici durante il periodo di previsione.
È probabile che il Nord America continui a mantenere la sua posizione dominante nel mercato dei prodotti biofarmaceutici durante il periodo di previsione. Gli Stati Uniti detenevano la quota di mercato maggiore in questa regione nel 2022. Secondo il rapporto dell’International Trade Administration, gli Stati Uniti sono il mercato più grande per i prodotti biofarmaceutici e rappresentano circa un terzo del mercato biofarmaceutico globale con pionieri nella ricerca e sviluppo biofarmaceutici. Inoltre, l’impatto economico dell’industria biofarmaceutica sull’economia statunitense è sostanziale. Nel 2018, oltre 17 miliardi di dollari di esportazioni biofarmaceutiche provenivano dalla maggior parte delle aziende di proprietà straniera che operano negli Stati Uniti. Inoltre, nello stesso anno, queste aziende a maggioranza straniera hanno speso circa 20 miliardi di dollari in ricerca e sviluppo.
D'altra parte, si prevede che l'Asia del Pacifico assisterà a una crescita redditizia nel periodo di previsione. Ciò è dovuto al fatto che l’industria biofarmaceutica cinese sta attraversando un enorme cambiamento, evolvendosi da un’attività incentrata sui farmaci generici a un fiorente polo di innovazione. Inoltre, la promozione dell'industrializzazione e la crescente applicazione di nuovi farmaci e di dispositivi e tecniche mediche di fascia alta sono alcuni dei fattori responsabili della crescita del mercato biofarmaceutico in Cina.
Secondo l'Information Technology & Secondo il rapporto della Innovation Foundation (ITIF), la Cina ha compiuto notevoli progressi nel raggiungere gli Stati Uniti in termini di innovazione. Inoltre, con una media di 36 indicatori, la Cina ha ridotto ad oggi il divario con gli Stati Uniti di un fattore competitivo pari a 1,5 (i fattori competitivi vengono identificati e valutati in base all'importanza relativa per raggiungere gli obiettivi strategici dell'azienda). Inoltre, dieci anni fa, la Cina era indietro dell’80% rispetto agli Stati Uniti; tuttavia, nel 2022, era al 50% a causa dei notevoli progressi nell’innovazione, nell’afflusso di tecnologia e nelle politiche industriali e commerciali favorevoli guidate dallo Stato. Inoltre, le approvazioni di nuovi prodotti per il trattamento delle malattie rare influenzano ulteriormente la crescita del mercato in Cina. Ad esempio, nel marzo 2022, CANbridge Pharmaceuticals Inc., un'azienda biofarmaceutica pioniera con sede in Cina, ha annunciato che la Taiwan Food and Drug Administration (TFDA) aveva accettato la richiesta di registrazione di nuovi farmaci/registrazione di farmaci orfani (NDA/ODR) per "CAN108 [ maralixibat soluzione orale (LIVMARLI TM)]" destinato al trattamento del prurito colestatico nei pazienti affetti da sindrome di Alagille (ALGS) di età pari o superiore a 1 anno.
Regioni redditizie per il mercato dei prodotti biofarmaceutici
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Biopharmaceuticals are complex medicines that are manufactured by extracting proteins and nucleic acids directly from biological sources using biotechnology. Most biopharmaceuticals are pharmaceutical products that are made from living organisms; transgenic organisms are genetically modified plants and animals, and this process is used to produce biopharmaceuticals; nevertheless, it is a controversial technology still in the testing phase.
Key factors that are driving the growth of this market are rising application in cancer therapeutics and potential to treat rare diseases are expected to boost the market growth for the biopharmaceuticals over the years.
The CAGR value of the biopharmaceuticals market during the forecasted period of 2022-2028 is 13.4%.
The monoclonal antibodies segment held the largest share of the market in the global biopharmaceuticals market and held the market share of 48.42% in 2022.
The biopharmaceuticals market majorly consists of the players such Amgen Inc, AbbVie Inc, Eli Lilly and Co, Bristol-Myers Squibb Co, Johnson & Johnson, Thermo Fisher Scientific Inc, AGC Biologics AS, Lonza Group AG, WuXi Biologics Inc, Boehringer Ingelheim International GmbH amongst others.
Eli Lilly and Co and Amgen Inc are the top two companies that hold huge market shares in the biopharmaceuticals market.
Global biopharmaceuticals market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the biopharmaceuticals market in 2022. With several North American market players focusing on research and development activities in the field of imaging technology, the regional market for biopharmaceuticals market is likely to propel in North America region during the forecast period.
The List of Companies - Biopharmaceuticals Market
- Amgen Inc.
- AbbVie Inc.
- Eli Lilly and Co
- Bristol-Myers Squibb Co
- Johnson & Johnson
- Thermo Fisher Scientific Inc
- AGC Biologics AS
- Lonza Group AG
- WuXi Biologics Inc
- Boehringer Ingelheim International GmbH.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Mar 2023
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Mar 2023
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2023
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Mar 2023
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Mar 2023
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Mar 2023
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Mar 2023
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)